Ganymed Raises Series C

GANYMED Pharmaceuticals AG, a Mainz, Germany-based developer of cancer antibodies, has raised EUR 33.7 million in Series C funding. VI Partners led the deal, and was joined by Future Capital, Ingro Finanz, Landesbank Baden-W